Context. LY3154885 (Eli Lilly and Company) is an oral D1 modulator. Lilly recently completed several clinical trials with LY3154207 ( mevidalen ), the first D1 positive allosteric modulator (D1PAM) with published clinical data, in Parkinson’s disease ( NCT02562768 ), sleep ( NCT02603861 ), and lewy body dementia (LBD) ( NCT03305809 ). In [...]
2 minute read
Mar. 12, 2022
LY3154885: an Oral D1 Modulator
LY3154885
oral D1 modulator Ph. I candidate for neurological disorders opt. against DDI w/ hepatocyte Cl assay J. Med. Chem. Eli Lilly and Company
Loading...
